Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis

Published:2023-04 Issue: Volume:72 Page:104561
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Ryerson Lana Zhovtis^ORCID,Foley John F,Defer Gilles,Cohen Jeffrey A,Arnold Douglas L,Butzkueven Helmut,Cutter Gary,Giovannoni Gavin,Killestein Joep,Wiendl Heinz,Sinks Susie,Kuhelj Robert,Bodhinathan Karthik,Lasky Tyler

Funder

Biogen

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference38 articles.

1. Exploratory magnetic resonance imaging endpoints from NOVA: a randomized controlled study of the efficacy of 6-week dosing of natalizumab vs continued 4-week treatment for multiple sclerosis;Arnold;Mult. Scler.,2022

2. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health Qual. Life Outcomes,2004

3. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis;Belachew;Eur. J. Neurol.,2011

4. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis;Benedict;Mult. Scler.,2017

5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N. Engl. J. Med.,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

2. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2);Neurology and Therapy;2024-07-24

3. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12

4. Gut-tropic T cells and extra-intestinal autoimmune diseases;Autoimmunity Reviews;2024-07

5. Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis;Journal of Neurology;2024-04-16